Table 1.
Baseline characteristics of the study groups
| Baseline characteristics | Group A (n = 142) |
Group B (n = 111) |
Group C (n = 15) |
P value |
|---|---|---|---|---|
| Age, years (mean ± SD) | 75.0 ± 12.3 | 76.9 ± 11.5 | 76.3 ± 8.9 | 0.426 |
| Male, n (%) | 84 (59.2) | 66 (59.5) | 12 (80.0) | 0.424 |
| Risk factors, n (%) | ||||
| Hypertension | 42 (29.6) | 27 (24.3) | 10 (66.7) | p < 0.05 |
| Diabetes mellitus | 17 (12.0) | 16 (14.4) | 8 (53.3) | p < 0.05 |
| Previous stroke | 21 (14.8) | 15 (13.5) | 2 (13.3) | 0.957 |
| Antithrombotic therapy | 20 (14.1) | 20 (18.0) | 3 (20.0) | 0.791 |
| Renal failure | 8 (5.6) | 4 (3.6) | 1 (6.7) | 0.867 |
| Tumor | 22 (15.5) | 21 (18.9) | 3 (20.0) | 0.857 |
| Preoperative use of goreisan | 14 (9.9) | 13 (11.7) | 1 (6.7) | 0.956 |
| Duration of preoperative use of goreisan, days (mean ± SD) | 3.58 ± 14.7 | 7.31 ± 47.7 | 8.6 ± 33.3 | 0.636 |
| Postoperative use of goreisan | 110 (77.5) | 82 (73.9) | 11 (73.3) | 0.872 |
Baseline clinical risk factors did not differ between the three groups, except for hypertension and diabetes mellitus. SD, standard deviation.